Summary

Goserelin acetate is a synthetic decapeptide agonist of gonadotropin-releasing hormone (GnRH). Like leuprolide, continuous administration produces pituitary desensitisation and gonadal suppression. With over 1,000 PubMed-indexed publications, goserelin is a well-established peptide therapeutic for hormone-dependent conditions. It is a licensed POM in the UK, available as Zoladex.

Overview

Goserelin acetate is a synthetic analogue of gonadotropin-releasing hormone (GnRH). It is a decapeptide with D-serine at position 6 and azaglycine at position 10, modifications that increase receptor binding affinity and resist enzymatic degradation. These changes produce a significantly longer duration of action compared to native GnRH.

Goserelin was developed by AstraZeneca (then ICI) and launched in the UK in 1987 as Zoladex. It is formulated as a biodegradable depot implant for subcutaneous administration, providing sustained release over 1 or 3 months. Its primary licensed indications are prostate cancer, breast cancer (premenopausal), endometriosis, and uterine fibroids.

For research and educational purposes only. Goserelin is a licensed POM in the UK.

Mechanism of Action

Goserelin acts at GnRH receptors on anterior pituitary gonadotrophs with the same biphasic mechanism as other GnRH agonists:

  1. Initial flare: First administration stimulates LH and FSH release, causing a transient rise in gonadal steroids (testosterone or oestradiol).

  2. Sustained suppression: Continuous receptor activation leads to downregulation and desensitisation of pituitary GnRH receptors. LH and FSH secretion falls, and gonadal steroid production is suppressed to castrate levels.

The goserelin depot formulation provides constant (non-pulsatile) exposure, which is essential for achieving the sustained suppression phase. The pulsatile versus continuous paradigm was established by Knobil and colleagues in pioneering work on rhesus monkeys.

Research Summary

Evidence Grade: Strong

Goserelin has robust clinical evidence:

Prostate Cancer: The study by Vogelzang et al. (1995) and the meta-analysis by the Prostate Cancer Trialists' Collaborative Group confirmed that goserelin monotherapy produces survival outcomes equivalent to surgical castration in advanced prostate cancer.

Breast Cancer: The ZIPP trial (Baum et al., 2006) demonstrated that goserelin added to adjuvant therapy improves disease-free survival in premenopausal women with early breast cancer.

Endometriosis: RCTs by Garnett et al. (1995) and others confirm goserelin's efficacy in reducing endometriosis pain and implants through oestrogen suppression, comparable to danazol with a different side-effect profile.

Uterine Fibroids: Goserelin reduces fibroid volume and menorrhagia, commonly used pre-operatively to facilitate surgical intervention.

Key Studies

  1. Vogelzang NJ et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer. Journal of Urology. 1995;153(4):1271-1277.
  2. Baum M et al. (ZIPP trial). Adjuvant goserelin in premenopausal women with early breast cancer. Journal of Clinical Oncology. 2006;24(28):4531-4537.
  3. Garnett JD et al. Goserelin in the treatment of endometriosis. British Journal of Obstetrics and Gynaecology. 1995;102(Suppl 12):13-17.
  4. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Progress in Hormone Research. 1980;36:53-88.

Commonly Discussed Protocols

All information is for research and educational purposes only. Goserelin is a licensed POM — no protocols for unsupervised use are provided.

In published clinical literature:

  • Depot implant: 3.6 mg every 28 days or 10.8 mg every 12 weeks, subcutaneous (abdominal wall)
  • Research dosing in animal models: Varies widely by species and study design; typically 0.1-1 mg/kg equivalents
  • In vitro research: 1-100 nM for GnRH receptor-expressing cell lines

Stacking

No established research protocols combine goserelin with other peptides. In clinical oncology, goserelin is combined with anti-androgens or aromatase inhibitors in combined hormonal therapy regimens, but this is outside the scope of research-peptide use.

Storage and Reconstitution

  • Storage: Store at 2-8 degrees C (refrigerated). Do not freeze. Depot implants come in pre-filled syringes and should be kept in original packaging.
  • Reconstitution: Commercial goserelin comes as a pre-formulated depot implant requiring no reconstitution. For laboratory research, lyophilised goserelin should be dissolved in sterile PBS or bacteriostatic water.
  • Stability: Store reconstituted research material at -20 degrees C. Avoid repeated freeze-thaw cycles.

Blood Work

In clinical and research contexts involving goserelin:

  • Testosterone (males) / Oestradiol (females): Confirm suppression to castrate levels within 3-4 weeks of initiation
  • LH and FSH: Verify pituitary desensitisation
  • Bone density (DEXA): Long-term goserelin causes significant bone mineral density loss; monitoring is essential
  • Lipid panel: Monitor for lipid profile changes
  • PSA (males): Monitor in prostate cancer contexts
  • HbA1c and fasting glucose: Monitor metabolic effects during prolonged use

UK Legal Status

Goserelin is a licensed prescription-only medicine (POM) in the UK, regulated by the MHRA. It is available as Zoladex (AstraZeneca). It is not a controlled substance under the Misuse of Drugs Act.

Research-grade goserelin for in vitro or laboratory research may be available from established chemical supply houses with appropriate purity documentation. Any use in humans without a prescription is illegal.

Vetted UK Vendors

As goserelin is a licensed POM, it is not sold as a research peptide by the vetted vendors listed on Peptide Data. Researchers requiring goserelin for legitimate laboratory research should source it through established chemical supply houses with HPLC-verified purity documentation.

References

  1. Vogelzang NJ et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. J Urol. 1995;153(4):1271-1277. PMID: 7861533.
  2. Baum M et al. Adjuvant goserelin in premenopausal women with early breast cancer (ZIPP). J Clin Oncol. 2006;24(28):4531-4537. doi:10.1200/JCO.2006.05.5749.
  3. Garnett JD et al. Goserelin in the treatment of endometriosis. Br J Obstet Gynaecol. 1995;102(Suppl 12):13-17.
  4. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53-88.

References

  1. Vogelzang NJ et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. J Urol. 1995;153(4):1271-1277. PMID: 7861533.
  2. Baum M et al. Adjuvant goserelin in premenopausal women with early breast cancer (ZIPP). J Clin Oncol. 2006;24(28):4531-4537. doi:10.1200/JCO.2006.05.5749.
  3. Garnett JD et al. Goserelin in the treatment of endometriosis. Br J Obstet Gynaecol. 1995;102(Suppl 12):13-17.
  4. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53-88.